Mercados españoles cerrados

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
1,9800+0,0600 (+3,13%)
Al cierre: 04:00PM EST
1,9900 +0,01 (+0,51%)
Después del cierre: 07:49PM EST

Inovio Pharmaceuticals, Inc.

660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462
United States
267 440 4200

Empleados a tiempo completo317

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Jacqueline E. Shea Ph.D.CEO, Pres & Director698,85k908,99k1966
Mr. Peter D. KiesChief Financial Officer686,51k271,76k1963
Dr. Laurent M. Humeau Ph.D.Chief Scientific Officer672,26kN/A1967
Ben MatoneDirector of Investor RelationsN/AN/AN/A
Mr. Robert L. Crotty J.D.Gen. CounselN/AN/A1974
Ms. Asli GevgililiChief HR OfficerN/AN/AN/A
Mr. E. J. Brandreth MBASr. VP of Quality AssuranceN/AN/AN/A
Dr. Jeffrey SkolnikSr. VP of Clinical Devel.N/AN/AN/A
Mr. Robert J. Juba Jr.Sr. VP of Biological Manufacturing & Clinical Supply ManagementN/AN/AN/A
Mr. Daniel JordanSr. VP of Device Manufacturing OperationsN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.


Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Gobierno corporativo

El ISS Governance QualityScore de Inovio Pharmaceuticals, Inc., a día 28 de noviembre de 2022, es 4. Las puntuaciones base son Auditoría: 8; Tablero: 2; Derechos de los accionistas: 4; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.